SKSandra L. Kweder

Sandra L. Kweder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sandra L. Kweder has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Leyla Sahin

    Office of New Drugs, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

    2 shared publications
  • Lynne Yao

    Office of New Drugs, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

    2 shared publications
  • Shannon Thor

    Europe Office, Office of Global Policy and Strategy US Food and Drug Administration Silver Spring Maryland USA

    2 shared publications
  • Agnes Saint-Raymond

    International Affairs Division, European Medicines Agency, Amsterdam, the Netherlands

    1 shared publication
  • Agnes Saint‐Raymond

    European Medicines Agency Amsterdam The Netherlands

    1 shared publication
  • Christelle Bouygues

    Scientific and Regulatory Management Department, Human Medicines Evaluation Division, European Medicines Agency, Amsterdam, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    A Comparison of FDA and EMA Pregnancy and Lactation Labeling

    by Dana Kappel, Leyla Sahin, Lynne Yao, Shannon Thor, Sandra Kweder

    The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have robust collaboration and dialogue around the need for data and the inclusion of pregnant and lactating individuals in clinical trials. Despite this collaboration, the two agencies have their own standards for the format and content of labeling for these populations. To understand these differences, the pregnancy and lactation labeling sections for 31 approved drugs were compared, and trends were assessed for use of language concordance and discordance related to use during pregnancy and lactation between the 2 agencies. Further analysis evaluated the presence of human data included in the labeling. The EMA and the FDA had high discordance between pregnancy and lactation labeling language, in 68% and 71% of labeling, respectively, and only 10% of pregnancy labeling and 16% of lactation labeling include human data. Concordance in labeling language is not the norm but occurs when there is a sizeable body of human data, animal data suggesting a particular safety issue, drug mechanism of action information, or disease‐specific considerations. This study highlights the need for more human data to inform prescribing decisions in these populations. The results also suggest that there is an opportunity for alignment in labeling across regions.


  • Open Access

    Assuring Access to Safe Medicines in Pregnancy and Breastfeeding

    by Janet Nooney, Shannon Thor, Corinne de Vries, John Clements, Leyla Sahin, Wei Hua, Darcie Everett, Cosimo Zaccaria, Robert Ball, Agnes Saint‐Raymond, et al.

    Scientists and regulators in Europe and the United States continue to seek methods and strategies to improve knowledge on rational use of medicines for pregnant and breastfeeding populations, an important subset of women’s health. Regulatory agencies have made strides toward improvement, but much more is needed. Recognizing the importance of international collaboration, we have begun to consider how to address these important public health issues more globally. The health of the child begins with the health of the mother.


  • Open Access

    Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?

    by Tania Teixeira, Sandra L. Kweder, Agnes Saint‐Raymond

    There is talk of regulatory collaboration worldwide to protect public health and allow patients timely access to medicines. Here, we present the reality of the collaboration between the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). This takes the form of near daily interactions, which may be less known outside of regulatory agencies. We present a review of what we call clusters, which involve the EMA, the FDA, and many other agencies under the umbrella of confidentiality arrangements. Through a survey of participants, we identified about 30 clusters of variable composition; these allow for the exchange of information and discussion among experts of applying regulatory science to common challenges in global drug development at every phase of its lifecycle and facilitate global medicines development.


  • Open Access

    A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014–2016: Concordance, Discordance, and Why

    by Mwango Kashoki, Zahra Hanaizi, Stella Yordanova, Richard Veselý, Christelle Bouygues, Jordi Llinares, Sandra L. Kweder

    The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have robust scientific and technical collaborations. As a window to the impact of these activities we compared the agencies’ decisions on drug marketing applications. Decisions were compared for 107 new drug applications with a regulatory outcome at both agencies in the period 2014–2016. Further analysis addressed individual applications for which the agencies had differing outcomes in terms of marketing approval, type of approval, and approved indication, including reasons underlying differences. The EMA and the FDA had high concordance (91–98%) in decisions on marketing approvals. Divergence in approval decisions, type of approval, and approved indication were primarily due to differences in agencies’ conclusions about efficacy based on review of the same data or differing clinical data submitted to support the application. This high rate of concordance suggests that engagement and collaboration on regulatory science has a positive impact.


  • Drug Shortages: The Cycle of Quantity and Quality

    by S L Kweder, S Dill

    Shortages of pharmaceutical drugs pose a serious and growing threat to public health. Although the number of drugs in shortage in the United States in any given year is very small, the number of prescription drug shortages in the country nearly tripled between 2005 and 2010. Drug shortages are becoming more severe as well as more frequent. The affected medicines include cancer treatments, anesthesia drugs, and other drugs that are critical to the treatment and prevention of serious diseases and life-threatening conditions. (The White House, Office of the Press Secretary, Executive Order 13588-Reducing Prescription Drug Shortages (http://www.whitehouse.gov/the-press-office/2011/10/31/executive-order-reducing-prescription-drug-shortages)).